Lexent Bio partners on NGS with Illumina

2019 05 10 17 42 3167 Lab Doctors Dna 400

San Francisco-based Lexent Bio has signed a nonexclusive deal to adapt its lead investigational Confera Dx next-generation sequencing (NGS) cancer test for use with Illumina's NextSeq 550Dx sequencer.

Confera Dx is designed to monitor treatment response and the level of minimal residual disease (MRD) in cancer patients. The company plans to launch the product as a laboratory-developed test (LDT) with testing done at its own CLIA lab, and Lexent will also pursue clearance by the U.S. Food and Drug Administration (FDA) to enable use in the local labs of hospitals and health systems.

In its tie-up with Illumina, Lexent will manage regulatory approvals and Illumina will sell associated sequencing consumables for the NextSeq system.

Page 1 of 4
Next Page